{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'For subjects transitioning to dialysis, SBP, DBP and HR will be measured pre', 'and post-dialysis, whenever possible (e.g., in-center HD). Otherwise these', 'assessments will be done between dialysis sessions.', '9.5.3.', 'Electrocardiograms', 'ECG measurements will be taken at the time points specified in the SoA (Section 2). Full', '12-lead ECGs will be recorded with the participant in a supine position. HR, PR interval,', 'QRS duration, and QT (uncorrected) interval will be measured. QTcB will be calculated', '(machine-read or manually).', 'When an ECG is performed, two additional ECGs are required if the initial ECG', 'indicates prolonged QTc (see Section 6.2) using the automated or manually calculated', 'QTcB value. The average QTcB value of all three ECGs will be used to determine', 'eligibility (see Section 6.2). Additional details are provided in the SRM.', 'ECG data will be read locally by a physician with experience in reading and interpreting', 'ECGs. The over-read of the ECG will be required to confirm eligibility. Additional', 'details are provided in the SRM.', 'All ECGs will be performed before measurement of SBP, DBP and HR and collection of', 'blood samples for laboratory testing.', 'For subjects transitioning to dialysis, ECGs will be performed before measurement of', 'SBP, DBP, HR and before collection of blood samples for laboratory testing, where', 'applicable (e.g., would not apply if ECG is performed post-HD).', '9.5.4.', 'Ultrasound', 'An ultrasound of the kidneys and adrenal glands will be performed prior to', 'randomization. It is understood that the adrenal glands will not always be able to be', 'visualized. Non-visualization of the adrenals is not a reason to exclude a participant from', 'randomization. Further details are provided in the SRM.', 'A documented ultrasound of the kidneys within the 6 months prior to screening may be', 'used to assess entry criteria (see Section 6.2), provided the size and cyst category has', 'been reported. If a more sensitive imaging study (e.g., MRI, CT) has been performed', 'within this timeframe and a report is available, this may be used in place of the', 'ultrasound.', 'For randomized participants with ADPKD:', 'An ultrasound of the kidneys will be performed when participants permanently', 'discontinue study treatment, preferably within one month of discontinuation of study', 'treatment as soon as clinically feasible. This may occur during the study OR at the', 'end of study. See Table 1 and Table 3 for details.', 'As clinically feasible, an ultrasound should be performed PRIOR to the following:', 'Transition to dialysis', 'Bilateral nephrectomy', '60']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Kidney transplant.', 'An additional ultrasound may be performed at any time during the study based on', \"investigator's clinical judgment (e.g., deterioration of kidney function as measured by\", 'eGFR in the absence of other identifiable causes). Other imaging techniques (e.g.,', \"MRI) can be performed at the investigator's discretion.\", 'If an additional imaging study is performed, and the condition of the cystic disease in', 'the kidney(s) has worsened more than expected given the clinical scenario, then', 'study treatment should be temporarily stopped. Subsequently, if no other cause', 'for the kidney function decline and/or cyst enlargement can be identified, study', 'treatment should be permanently discontinued after consultation with the Medical', 'Monitor.', '9.5.5.', 'Clinical Laboratory Assessments', 'Refer to Table 8 for the list of clinical laboratory tests to be performed and to the', 'SoA (Section 2) for the timing and frequency.', 'The investigator must review the laboratory report, document this review, and', 'record any clinically relevant changes occurring during the study in the AE', 'section of the CRF. The laboratory reports must be filed with the source', 'documents. Clinically significant abnormal laboratory findings are those which', 'are not associated with the underlying disease, unless judged by the investigator', \"to be more severe than expected for the participant's condition.\", 'All laboratory tests with values that are considered clinically significantly', 'abnormal during participation in the study or within seven days after the last', 'dose of randomized treatment should be repeated until the values return to', 'normal or baseline. If such values do not return to normal within a period', 'judged reasonable by the investigator the sponsor should be notified.', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the investigator, the etiology should be identified and the sponsor', 'notified.', 'All protocol-required laboratory assessments, as defined in Table 8, must be', 'conducted in accordance with the laboratory manual and the SoA (Section', '2). Laboratory assessments will be performed by a central laboratory with the', 'exception of HemoCue Hgb and urine pregnancy tests which will be performed', 'at the clinical site. The results of each HemoCue Hgb must be entered into the', \"participant's eCRF.\", 'Local laboratory results are only required in the event that the central laboratory', 'results are not available in time for either study treatment administration and/or', 'response evaluation. If a local sample is required, it is important that the sample', 'for central analysis is obtained at the same time.', '61']\n\n###\n\n", "completion": "END"}